The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.
 
Daniel Wilhelm Mueller
No Relationships to Disclose
 
Thorsten Oliver Goetze
Honoraria - Bayer; Celgene; Lilly; MSD; SERVIER; Shire
Consulting or Advisory Role - Bayer; Celgene; Lilly; MSD; SERVIER; Shire
Speakers' Bureau - Lilly; MCI Group; MSD
Research Funding - Deutsche Forschungsgemeinschaft; Gemeinsamer Bundesausschuss
 
Akin Atmaca
Honoraria - Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
 
Mohammad-Reza RAFIYAN
Consulting or Advisory Role - Ipsen; Janssen; Roche; Sanofi
 
Eckhart Weidmann
Consulting or Advisory Role - MorphoSys; Roche
Travel, Accommodations, Expenses - Celgene
 
Christian H. Brandts
Honoraria - Bristol-Myers Squibb; Janssen Oncology; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen Oncology; Novartis
 
Urs Pabst-Giger
No Relationships to Disclose
 
Markus Duex
No Relationships to Disclose
 
Thomas Werner Kraus
No Relationships to Disclose
 
Simon Stahn
No Relationships to Disclose
 
Regina Eickhoff
No Relationships to Disclose
 
Salah-Eddin Al-Batran
Leadership - IKF Klinische Krebsforschung
Stock and Other Ownership Interests - IKF Klinische Krebsforschung
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Sharp & Dohme; Nordic Bioscience; Roche
Speakers' Bureau - AIO gGmbH; Celgene; Forum für Medizinische Fortbildung; Lilly; MCI group; Nordic Bioscience; Promedior; Roche
Research Funding - Celgene; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Lilly; Medac; Merck; Roche; Sanofi; Vifor Pharma